Daily Brief India: Innova Captab and more

• Innova Captab is a top-tier Indian Contract Development and Manufacturing Organization (CDMO) with strong vertical integration across Active Pharmaceutical Ingredients (APIs) and finished formulation dosage forms, currently partnering with 14 of India’s top 15 pharmaceutical companies.
• Financial performance reflects robust scaling, with annual revenue expanding from INR 10,773.86M in 2024 to INR 16,051.02M in 2026 (~22% CAGR) and Net Income reaching INR 1,431.83M, supported by a pivotal inflection to positive Free Cash Flow of INR 340.72M in 2026 as major capital expenditures mature.
• Structural tailwinds from mandatory revised Schedule M compliance enforcement are driving industry consolidation toward organized CDMOs; however, Innova’s current valuation of 43.0x P/E and 6.2x P/B reflects an earned premium over pure formulation peers, requiring sustained capacity ramp-up and margin execution at its newly commissioned Jammu facility.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.